<i>Lentinus edodes</i>Suppresses Allergen-Induced Airway Hyperresponsiveness and Inflammation by Downregulating Nuclear Factor-kappa B Activity in a Murine Model of Allergic Asthma

Yan, Guang; Choi, Yun Ho

doi:10.11637/kjpa.2014.27.2.79

Cited by 2 publications

(1 citation statement)

References 33 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AHR was measured 2 days after the last OVA challenge as described previously . Briefly, Mice were exposed to increasing doses of aerosolized methacholine (MCh, Sigma‐Aldrich), and the resulting AHR was measured by the lung resistance (R L ) in tracheostomized mice.…”

Section: Methodsmentioning

confidence: 99%

Recombinant pyrin domain protein attenuates allergic inflammation by suppressing NF‐κB pathway in asthmatic mice

Piao

Choi

et al. 2018

Scand J Immunol

Self Cite

View full text Add to dashboard Cite

Pyrin domain (PYD), a subclass of protein motif known as the death fold, is frequently involved in inflammation and immune responses. PYD modulates nuclear factor-kappa B (NF-κB) signalling pathway upon various stimuli. Herein, a novel recombinant pyrin domain protein (RPYD) was generated. Its role and mechanism in inflammatory response in an ovalbumin (OVA) induced asthma model was investigated. After OVA challenge, there was inflammatory cell infiltration in the lung, as well as airway hyper-responsiveness (AHR) to inhaled methacholine. In addition, eosinophils increased in the bronchoalveolar lavage fluids, alone with the elevated levels of Th-2 type cytokines [interleukin (IL)-4, IL-5 and IL-13], eotaxin, and adhesion molecules. However, the transnasal administration of RPYD before the OVA challenge significantly inhibited these asthmatic reactions. Moreover, RPYD markedly suppressed NF-κB translocation, reduced phosphorylation of p38 MAPK, and thus attenuated the expression of intercellular adhesion molecule 1 and IL-6 in the BEAS-2B cells stimulated by proinflammatory cytokines in vitro. These findings indicate that RPYD can protect asthma host from OVAinduced airway inflammation and AHR via down-regulation of NF-κB and p38 MAPK activities. RPYD may be used as a potential medicine for the treatment of asthma in clinic.Piao and Choi are contributed equally to this work and should be considered co-first authors.

show abstract

Section: Methodsmentioning

confidence: 99%